Evidence map›Paper›PMID 41984266›Full record

ReviewMikrochimica acta2026

Lateral flow immunochromatographic assay (LFIA) for tumor marker detection: technical evolution, clinical translation challenges, and future perspectives.

Siyuan Zhao, Yinglin Wang, Chentao Li, Yafang Wu, Jinlong Jiao, Yuxi Zhang, Dezhi Li, Qing Liu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Siyuan Zhao *School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, PR China.
Yinglin Wang *School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, PR China.
Chentao LiSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, PR China.
Yafang WuSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, PR China.
Jinlong JiaoSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, PR China.
Yuxi ZhangSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, PR China.
Dezhi LiSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, PR China.
Qing LiuSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, PR China. liuq@usst.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor markers are of great value for predicting tumor progression and clarifying the molecular mechanisms of tumorigenesis. In terms of rapid detection, lateral flow immunoassay (LFIA) has become a key tool for tumor marker detection, favored for its speed, cost-effectiveness, and ease of operation—all of which are crucial for early cancer screening, treatment monitoring, and point-of-care testing (POCT) in various settings. Although widely used to detect core markers, LFIA performance is limited by signal tracers, antibody affinity, and test strip design; these issues need to be addressed to expand its clinical utility. This review summarizes the latest progress of LFIA in tumor marker detection over the past five years, highlighting marker-specific detection optimizations, novel test strip devices, and integrated innovations with artificial intelligence/machine learning. These innovations significantly outperform traditional readout methods in quantitative accuracy. The review also outlines multi-dimensional strategies for sensitivity enhancement (dual/multimodal detection, sensor structure optimization, auxiliary signal amplification) and identifies future development trends, such as improving multiplex detection, adapting to non-invasive samples, and standardizing production, ultimately advancing LFIA from qualitative screening to a clinically reliable tool for precision oncology.

Indexed as

Biomarkers, TumorChromatography, AffinityHumansImmunoassayRapid Diagnostic TestsBiomarkers, TumorEarly cancer detectionLateral flow assayNanomaterialsPoint-of-care analysisTumor markers

Identifiers

PMID41984266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.